Drugs / Cimetidine
Cimetidine
also known as
Acid-eze · Aciloc · Acinil · Acitak 200 · Acitak 400 · Acitak 800 · Brumetadina · Brumetidina · +26 more
Small molecule targets HRH2 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 15 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (2) | US (FDA) | TAGAMET HB | — | 1995-11-15 – 1998-06-05 | fda.gov ↗ |
| Label expansions (12) | US (FDA) | TAGAMET | — | 1979-03-16 – 1991-11-13 | fda.gov ↗ |
| Approved | US (FDA) | TAGAMET | — | 1977-08-16 | fda.gov ↗ |
Trials 18
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05365451 | Apr 2022 → Jul 2023 | — | Washington State University | Completed | No outcome recorded |
| Phase 110 trials | ||||||
| Phase 1 | NCT05881811 | Mar → Apr 2023 | postherpetic neuralgia | Haisco Pharmaceutical Group Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04493931 | Aug → Dec 2020 | bacterial infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT03618316 | Jun → Jul 2018 | — | Poxel SA | Completed | No outcome recorded |
| Phase 1 | NCT03380455 | Jan 2018 | — | Idorsia Pharmaceuticals Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03307252 | Oct 2017 → May 2018 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT01536249 | Mar → Apr 2012 | amyotrophic lateral sclerosis | Knopp Biosciences | Completed | No outcome recorded |
| Phase 1 | NCT01169012 | Sep 2010 → Apr 2012 | acute lymphoblastic leukemia, acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome | UNC Lineberger Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT01010698 | Jun 2009 → Dec 2012 | — | University of Maryland, Baltimore | Completed | No outcome recorded |
| Phase 1 | NCT00800280 | Jan → Feb 2009 | generalized anxiety disorder | Pfizer | Terminated | No outcome recorded |
| Phase 1 | NCT02172417 | Jul → Nov 2000 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05922358 | Sep 2023 → Sep 2025 overdue | digestive system neoplasm | Fujian Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT00002733 | Jan 1996 → Jan 2000 | cutaneous melanoma, kidney cancer | Hoag Memorial Hospital Presbyterian | Completed | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT06056583 | Dec 2023 → Sep 2028 expected | lactation disease, puerperal disorder | University of Washington | Recruiting | No outcome recorded |
| Phase 4 | NCT02703896 | Jan 2012 | lung disorder | King Saud University | Completed | No outcome recorded |
| Phase 4 | NCT01256879 | Mar 2011 → Apr 2014 | — | University of Maryland, Baltimore | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT00475059 | Mar 2007 → Mar 2008 | — | University Hospital of Saint-Etienne | Completed | No outcome recorded |
| — | NCT00002092 | — | HIV infectious disease | Community Research Initiative of New England | Completed | No outcome recorded |
| Comparator or background therapy13 trials | ||||||
| Phase 1 | NCT03619954 Background | Jul 2018 → Jul 2019 | — | Anhui Provincial Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT02202512 Comparator | Sep → Dec 2014 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02287272 Comparator | May → Jul 2014 | chronic obstructive pulmonary disease | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 2 | NCT05866510 Background | May 2023 → Apr 2024 | esophageal cancer | Peking University | Unknown | No outcome recorded |
| Phase 2 | NCT05020184 Comparator | Jun 2022 → Apr 2025 | X-linked erythropoietic protoporphyria | Amy K. Dickey, M.D. | Completed | No outcome recorded |
| Phase 2 | NCT01953536 Background | Apr 2014 → Nov 2016 | breast neoplasm | Endocyte | Withdrawn | No outcome recorded |
| Phase 2 | NCT00515073 Background | Apr 2001 → May 2013 | endometrial cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2/3 | NCT04862585 Comparator | Oct 2021 → Jun 2024 | breast carcinoma in situ, female breast carcinoma | Ohio State University Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 3 | NCT05673590 Background | May 2023 → Jun 2025 | non-small cell lung carcinoma | Beijing Biostar Pharmaceuticals Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT04018131 Comparator | Mar 2018 → Mar 2020 | atopic eczema | Faculty of Medicine, University of Indonesia | Unknown | No outcome recorded |
| Phase 3 | NCT02157376 Comparator | Jul 2014 → Feb 2016 | active peptic ulcer disease | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT01757275 Comparator | Feb 2013 → Dec 2014 | active peptic ulcer disease | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00045799 Comparator | May 2002 → May 2003 | — | Bausch Health Americas, Inc. | Completed | No outcome recorded |
Evidence & citations 39 cited values
Every value below carries the sentence it was read from. 32 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cimetidine | “Before the use of utidelone, all patients will accept pretreatment: diphenhydramine 40 mg by intramuscular injection or oral administration, and dexamethasone10 mg and...” NCT05866510 ↗30“Pretreatment: diphenhydramine 40 mg by intramuscular injection or oral administration, and dexamethasone10 mg and cimetidine 300 mg by intravenous injection 30 minutes prior to...” NCT05673590 ↗ “cimetidine 300 mg IV or ranitidine 50 mg IV 30 to 60 minutes prior to paclitaxel.” NCT01953536 ↗ “Intravenous Clofarabine (10mg/m2) Oral clofarabine (30mg/m2) Cimetidine (800mg)” NCT01169012 ↗ “Capsules and solutions in this research contain the drug cimetidine.” NCT01256879 ↗ “cimetidine 40mg iv, promethazine 25mg im” NCT05922358 ↗ “Group T (cimetidine 200 mg)” NCT02703896 ↗ “Cimetidine 0.4g i.v.” NCT03619954 ↗ |
| Known as | Acid-eze | ChEMBL registry synonym — accepted as the source's own label CHEMBL30 ↗ |
| Known as | Aciloc | ChEMBL registry synonym — accepted as the source's own label CHEMBL30 ↗ |
| Known as | Acinil | ChEMBL registry synonym — accepted as the source's own label CHEMBL30 ↗ |
| Known as | Acitak 200 | ChEMBL registry synonym — accepted as the source's own label CHEMBL30 ↗ |
| Known as | Acitak 400 | ChEMBL registry synonym — accepted as the source's own label CHEMBL30 ↗ |
| Known as | Acitak 800 | ChEMBL registry synonym — accepted as the source's own label CHEMBL30 ↗ |
| Known as | Brumetadina | ChEMBL registry synonym — accepted as the source's own label CHEMBL30 ↗ |
| Known as | Brumetidina | ChEMBL registry synonym — accepted as the source's own label CHEMBL30 ↗ |
| Known as | Cimal | ChEMBL registry synonym — accepted as the source's own label CHEMBL30 ↗ |
| Known as | Cimetidina | ChEMBL registry synonym — accepted as the source's own label CHEMBL30 ↗ |
| Known as | Cimetidine hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL30 ↗ |
| Known as | CIMETIDINE HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL30 ↗ |
| Known as | Cimetidinum | ChEMBL registry synonym — accepted as the source's own label CHEMBL30 ↗ |
| Known as | Dyspamet | ChEMBL registry synonym — accepted as the source's own label CHEMBL30 ↗ |
| Known as | Galenamet | ChEMBL registry synonym — accepted as the source's own label CHEMBL30 ↗ |
| Known as | Gastromet | ChEMBL registry synonym — accepted as the source's own label CHEMBL30 ↗ |
| Known as | Kentamet | ChEMBL registry synonym — accepted as the source's own label CHEMBL30 ↗ |
| Known as | NSC-335308 | ChEMBL registry synonym — accepted as the source's own label CHEMBL30 ↗ |
| Known as | Peptimax 200 | ChEMBL registry synonym — accepted as the source's own label CHEMBL30 ↗ |
| Known as | Peptimax 400 | ChEMBL registry synonym — accepted as the source's own label CHEMBL30 ↗ |
| Known as | Peptimax 800 | ChEMBL registry synonym — accepted as the source's own label CHEMBL30 ↗ |
| Known as | SKF-92334 | ChEMBL registry synonym — accepted as the source's own label CHEMBL30 ↗ |
| Known as | Stomedine | ChEMBL registry synonym — accepted as the source's own label CHEMBL30 ↗ |
| Known as | Tagadine | ChEMBL registry synonym — accepted as the source's own label CHEMBL30 ↗ |
| Known as | Tagamet | “Tagamet” NCT06056583 ↗ |
| Known as | Tagamet 100 | ChEMBL registry synonym — accepted as the source's own label CHEMBL30 ↗ |
| Known as | Tagamet hb | ChEMBL registry synonym — accepted as the source's own label CHEMBL30 ↗ |
| Known as | Tagamet hb 200 | ChEMBL registry synonym — accepted as the source's own label CHEMBL30 ↗ |
| Known as | Ulcedin | ChEMBL registry synonym — accepted as the source's own label CHEMBL30 ↗ |
| Known as | Ulcimet | ChEMBL registry synonym — accepted as the source's own label CHEMBL30 ↗ |
| Known as | Ulcomedina | ChEMBL registry synonym — accepted as the source's own label CHEMBL30 ↗ |
| Known as | Ultec | ChEMBL registry synonym — accepted as the source's own label CHEMBL30 ↗ |
| Known as | Valmagen | ChEMBL registry synonym — accepted as the source's own label CHEMBL30 ↗ |
| Known as | Zita | ChEMBL registry synonym — accepted as the source's own label CHEMBL30 ↗ |
| Action | Inhibit | “Cimetidine (probe inhibitor of the organic cation transport in the kidneys)” NCT02287272 ↗1“Histamine H2 receptor antagonist” CHEMBL30 ↗ |
| Modality | Small molecule | — CHEMBL30 ↗ |
| Route | Oral | “oral cimetidine” NCT00002733 ↗ |
| Target | HRH2 | “Histamine H2 receptor antagonist” CHEMBL30 ↗ |